NR 566 Week 8 Final Review

1. Question: Antacids MOA 2. Question: which antacids have the highest absolute neutrophil count (ANC)? 3. Question: what do calcium containing antacids needs for absorption? 4. Question: Antacid Indications 5. Question: Monitoring after given antiviral for flu 6. Question: 1st line therapy for uncomplicated UTI 7. Question: what causes ophthalmia neonatorum 8. Question: patient education for albendazole & mebendazole 9. Question: patient education for ivermectin 10. Question: patient education for ibendazole 11. Question: Aminopenicillins Drugs 12. Question: Fluoroquinolone older drugs 13. Question: Fluoroquinolones new drugs 14. Question: Macrobid indication 15. Question: the most common cause of Traveler's diarrhea 16. Question: PUD stepped-approach algorithm 17. Question: what causes most diarrhea? 18. Question: symptomatic treatment for viral URIs 19. Question: 1st lines therapy for acute otitis media (AOM) & sinusitis 20. Question: When aminopenicillins are combined with beta-lactamase inhibitors 21. Question: beta-lactamase inhibitors that can be combined with aminopenicillins 22. Question: Penicillinase-resistant penicillins drugs 23. Question: Penicillinase-resistant penicillins active against 24. Question: Anti-pseudomonal penicillin drugs 25. Question: Anti-pseudomonal penicillins active against 26. Question: 1st generation cephalosporins drugs 27. Question: 1st generation cephalosporins active against 28. Question: 2nd generation cephalosporins drugs 29. Question: 3rd generation cephalosporins drugs 30. Question: 4th generation cephalosporins drugs 31. Question: 2nd generation cephalosporins active against 32. Question: 3rd generation cephalosporins active against 33. Question: 4th generation cephalosporins active against primarily 34. Question: which cephalosporins are best against gram (+) organisms 35. Question: ADR for cephalosporins 36. Question: indications for cephalosporins 37. Question: Pharmacodynamics of cephalosporins 38. Question: fluoroquinolones active against 39. Question: Pharmacodynamics of fluoroquinolines 40. Question: Fluoroquinolones indications 41. Question: black box warning for fluoroquinolones 42. Question: macrolide drugs 43. Question: Pharmacodynamics of macrolides 44. Question: macrolides are active against 45. Question: Macrolide indications 46. Question: Macrolide drug interactions 47. Question: sulfonamide drugs 48. Question: sulfonamide drugs active against 49. Question: sulfonamide indications 50. Question: Pharmacodynamics of sulfonamides 51. Question: Trimethoprim mechanism of action 52. Question: Trimethoprim active against 53. Question: Nitrofurantoin mechanism of action 54. Question: Nitrofurantoin active against 55. Question: sulfonamide drug interactions 56. Question: nitrofurantoin drug interactions 57. Question: sulfonamide ADR 58. Question: AIDS and sulfonamides 59. Question: Nitrofurantoin ADR 60. Question: ADR with G6PD and sulfonamides 61. Question: blood dyscrasias and sulfonamides 62. Question: Bactrim indications 63. Question: Bactrim drug interactions 64. Question: Clindamycin indications 65. Question: clindamycin ADRs 66. Question: Clindamycin mechanism of action 67. Question: prophylaxis treatment for ophthalmia neonatorum 68. Question: most common UTI orgamisms 69. Question: 1st line therapy for uncomplicated UTI in adult woman 70. Question: Characteristics of Complicated UTI 71. Question: Recurrent UTI prevention 72. Question: indications for referral to Urologist 73. Question: Antimycobacterial drugs 74. Question: antimycobacterial mechanism of action 75. Question: active TB first phase (initiation phase) drugs 76. Question: active TB 2nd phase (continuation) drugs 77. Question: antiviral drugs: nucleoside analogues 78. Question: Acyclovir (Zovirax) indications 79. Question: Valacyclovir (Valtrex) indications 80. Question: famciclovir indications 81. Question: Ganciclovir indications 82. Question: Ribavirn indications 83. Question: antiviral (nucleoside analogues) mechanism of action 84. Question: Antivirals for Influenza (neuraminidase inhibitors) 85. Question: Antiviral Neuraminidase inhibitor mechanism of action 86. Question: Antifungal (Antimycotics) classes 87. Question: Azoles - Triazoles drugs 88. Question: Polyene Macrolides drugs 89. Question: Allylamines Drugs 90. Question: Nuclear acid synthesis inhibitor drugs 91. Question: Azoles mechanism of action 92. Question: Polyene Macrolides MOA 93. Question: Flucytosine mechanism of action 94. Question: Ketoconazole mechanism of action 95. Question: fluconazole & posaconazole mechanism of action 96. Question: itraconazole & voriconazole mechanism of action 97. Question: Clotrimazole indications 98. Question: Ketoconazole indications 99. Question: Fluconazole indications 100. Question: Itraconazole (Sporanox) indications 101. Question: Posaconazole (Noxafil) indications 102. Question: Voriconazole (Vfend) indications 103. Question: Terbinafine (Lamisil) indications 104. Question: Amphotericin B 105. Question: Griseofulvin indications 106. Question: Miconazole (Monistat) indications 107. Question: Antifungal monitoring 108. Question: Anthelmintic (antiparasitic) drugs 109. Question: Benzimidazoles MOA 110. Question: Pyrantel MOA 111. Question: Ivermectin MOA 112. Question: Mebendazole (Vermox) indications 113. Question: Nematodes 114. Question: Cestodes 115. Question: Trematodes 116. Question: Albendazole (Albenza) indication 117. Question: Pyrantel indications 118. Question: Ivermectin (Stromectol) indications 119. Question: Metronidazole (Flagyl), nitazoxanide, & tinidazole 120. Question: Metronidazole indications 121. Question: Nitazoxanide (Alinia) indications 122. Question: Tinidazole (Tindamax) indications 123. Question: Metronidazole MOA 124. Question: Nitazoxanide (Alinia) MOA 125. Question: tinidazole (Tindamax): MOA 126. Question: Metronidazole drug interactions 127. Question: bacterial vaginosis treatment 128. Question: Diagnosis of bacterial vaginosis 129. Question: cardinal symptoms of chronic bronchitis which indicate need for antibiotic 130. Question: Tinea corporis (ringworm) treatment 131. Question: Tinea pedis (athletes foot) treatment 132. Question: Tinea Capitis (Scalp Ringworm) treatment 133. Question: Tinea Cruris (Jock Itch) Treatment 134. Question: onychomycosis 135. Question: 1st line treatment for primary and secondary skin infections 136. Question: medications and dose to eradicate nasal MRSA 137. Question: treatment for acute sinusitis 138. Question: What is the 1st line therapy for GERD? 139. Question: Antacid ADRs 140. Question: Antacids: Drug Interactions 141. Question: antacid patient education 142. Question: lifestyle changed to prevent GERD symptoms 143. Question: Antidiarrheal classes 144. Question: Absorbent antidiarrheals drugs 145. Question: opiate antidiarrheals drugs 146. Question: anticholinergic antidiarrheals drugs 147. Question: Kaolin MOA 148. Question: pectin MOA 149. Question: Bismuth Subsalicylate MOA 150. Question: Lomotil (diphenoxylate/atropine) MOA 151. Question: motofen (difenoxin/atropine) MOA 152. Question: Loperamide (Imodium) MOA 153. Question: Crofelemer (Fulyzaq) indication 154. Question: antidiarrheal precautions/contraindications 155. Question: antidiarrheal ADRs 156. Question: antidiarrheal drug interactions 157. Question: Laxative classes 158. Question: laxative stimulant 159. Question: Osmotic laxatives 160. Question: Bulk producing laxative 161. Question: Lubricant laxatives 162. Question: surfactant laxative 163. Question: hyperosmolar laxative 164. Question: Chloride channel activators drugs 165. Question: Opioid receptor antagonists drugs 166. Question: laxative 1st line therapy 167. Question: Laxatives are contraindicated in 168. Question: laxative precautions 169. Question: Cytoprotective agents 170. Question: Clinical Pearl for polyethylene glycol electrolyte solution 171. Question: Sucralfate (Carafate) 172. Question: Misprostol (Cytotec) 173. Question: Cytoprotective Agents Side Effects 174. Question: Misoprostol precautions 175. Question: antiemetic classes 176. Question: Antihistamines antiemetics 177. Question: Phenothiazines antiemetics 178. Question: Cannaboids antiemetics 179. Question: 5-HT3 receptor antagonist antiemetics 180. Question: Anticholinergic antiemetics 181. Question: P/neurokinin 1 receptor antagonist antiemetic 182. Question: Mics antiemetic 183. Question: monitoring of long term use of promethazine 184. Question: antihistamine antiemetic precautions/ contraindications 185. Question: phenothiazine precautions/contraindications 186. Question: dronabinol precautions/contraindications 187. Question: 5-HT3 antagonists antiemetic precuations/contraindications 188. Question: Scopalamine (Transderm Scop) precuations/contraindications 189. Question: Aprepitant (Emend) precautions/contraindications 190. Question: Phenothiazines ADR 191. Promethazine (Phenergan) ADR 192. H2 receptor antagonists MOA 193. H2 receptor antagonists drugsCimetidine (Tagamet) 194. H2 receptor antagonists precuations/contraindications 195. H2 receptor antagonists ADR 196. H2 receptor antagonists drug inteactions 197. H2 receptor antagonists monitoring 198. H2 receptor antagonists patient education 199. Prokinetic drugs 200. prokinetic MOA 201. black box warning for metoclopramide (Reglan) 202. Metoclopramide (Reglan) pecaution/contraindications 203. Metoclopramide (Reglan) ADR 204. Metoclopramide (Reglan) drug interactions 205. Proton Pump Inhibitors (PPIs) MOA 206. Proton Pump Inhibitors (PPIs) indications 207. Proton Pump Inhibitors (PPIs) 208. PPI Precautions/Contraindications 209. PPI ADRs 210. PPI drug interactions 211. PPI black box warning 212. PPI monitoring 213. GERD management 214. PPI therapy for mod to severe GERD 215. PPI step up or step down approach 216. 1st line triple therapy for H. Pylori 217. 2nd line therapy for H. Pylori with PCN allergy 218. 2nd line therapy or rescue therapy for H. Pylori 219. IBS with constipation treatment 220. Traveler's Diarrhea Treatment 221. High risk destinations for traveler's diarrhea 222. Intermediate risk destinations for traveler's diarrhea 223. other causes of traveler's diarrhea 224. Bacterostatic 225. bacteriocidal 226. Bacteriostatic drugs 227. Bactericidal drugs 228. anti-microbial resistance 229. subclasses of Beta-lactams PCNS 230. Pharmacodynamics of Beta-lactam PCNs 231. 1st line therapy for Strep pharyngitis. 232. 1st line therapy for all bites 233. Natural PCN's, Drugs 234. Natural PCNs active against 235. Aminopenicillins active against